Efficacy and tolerability of lumiracoxib 100 mg once daily in knee osteoarthritis: a 13-week, randomized, double-blind study vs. placebo and celecoxib

References

• Reginster JY. The prevalence and burden of arthritis. Rheumatology 2002;41(Suppl 1):3–6
   PubMed Web of Science ®Google Scholar
• Sangha O. Epidemiology of rheumatic diseases. Rheumatology 2000;39(Suppl 2):3–12
   PubMed Web of Science ®Google Scholar
• Lawrence RC, Helmick CG, Arnett FC, Deyo RA, Felson DT, Giannini EH, Heyse SP, Hirsch R, Hochberg MC, Hunder GG, Liang MH, Pillemer SR, Steen VD, Wolfe F. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 1998;41:778–9
   PubMed Web of Science ®Google Scholar
• Jordan KM, Arden NK, Doherty M, Bannwarth B, Bijlsma JW, Dieppe P, Gunther K, Hauselmann H, Herrero-Beaumont G, Kaklamanis P, Lohmander S, Leeb B, Lequesne M, Mazieres B, Martin-Mola E, Pavelka K, Pendleton A, Punzi L, Serni U, Swoboda B, Verbruggen G, Zimmerman-Gorska I, Dougados M. Standing Committee for International Clinical Studies Including Therapeutic Trials ESCISIT. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2003;62: 1145–55
   Google Scholar
• American College of Rheumatology. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Arthritis Rheum 2000;43:1905–15
   PubMed Web of Science ®Google Scholar
• Schnitzer TJ. Update of ACR guidelines for osteoarthritis: role of the coxibs. J Pain Symptom Manage 2002;23(Suppl 4):S24–30
   PubMedGoogle Scholar
• Dougados M. The role of anti-inflammatory drugs in the treatment of osteoarthritis: a European viewpoint. Clin Exp Rheumatol 2001;19(Suppl 25):S9–14
   PubMedGoogle Scholar
• Moskowitz RW. The role of anti-inflammatory drugs in the treatment of osteoarthritis: a United States viewpoint. Clin Exp Rheumatol 2001;19(Suppl 25):S3–8
   PubMedGoogle Scholar
• Hernandez-Diaz S, Garcia Rodriguez LA. Epidemiologic assessment of the safety of conventional nonsteroidal antiinflammatory drugs. Am J Med 2001;110(Suppl 3A):20S–7
   Google Scholar
• Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs. N Engl J Med 1999;340:1888–99
   PubMed Web of Science ®Google Scholar
• Moore RA. The hidden costs of arthritis treatment and the cost of new therapy – the burden of non-steroidal anti-inflammatory drug gastropathy. Rheumatology 2002;41(Suppl 1):7–15
   PubMedGoogle Scholar
• Bensen WG, Fiechtner JJ, McMillen JI, Zhao WW Yu SS, Woods EM, Hubbard RC, Isakson PC, Verburg KM, Geis GS. Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomized controlled trial. Mayo Clin Proc 1999;74: 1095–105
   Google Scholar
• Goldstein JL, Correa P, Zhao WW, Burr AM, Hubbard RC, Verburg KM, Geis GS. Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis. Am J Gastroenterol 2001;96\(Suppl 4):1019–27
   Google Scholar
• Cannon GW Caldwell JR, Holt P McLean B, Seidenberg B, Bolognese J, Ehrich E, Mukhopadhyay S, Daniels B. Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium: results of a one-year, randomized clinical trial in patients with osteoarthritis of the knee and hip. Rofecoxib Phase III Protocol 035 Study Group. Arthritis Rheum 2000;43: 978–87
   Google Scholar
• Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC, Kvien TK, Schnitzer TJ. VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000;343:1520–28
   Google Scholar
• Brune K, Hinz B. Selective cyclooxygenase-2 inhibitors: similarities and differences. Scand J Rheumatol 2004;33:1–6
   PubMed Web of Science ®Google Scholar
• Warner TD, Mitchell JA. Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic. FASEB J 2004;18:790–804
   PubMed Web of Science ®Google Scholar
• Marshall PJ, Berry JC, Wasvary J, Van Duzer J, Scott G, Rordorf C, Milosavljev S, Fujimoto RA. The in vitro and in vivo selectivity of COX189, a new and highly selective inhibitor of COX-2. Ann Rheum Dis 2002;61(Suppl I):259 [Abstract SAT0013]
   Google Scholar
• Hartmann S, Scott G, Rordorf C, Campestrini J, Branson J, Keller U. Lumiracoxib demonstrates high absolute bioavailability in healthy subjects. In: European collaboration: Towards drug development and rational drug therapy. Proceedings of the Sixth Congress of the European Association for Clinical Pharmacology and Therapeutics. Tulunay FC, Orme M, editors. Berlin: SpringerVerlag, 2003;pp 124 [Abstract P–199]
   Google Scholar
• Scott G, Rordorf C, Blood P, Branson J, Milosavljev S, Greig G. Dose escalation study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of COX189 in healthy subjects. Ann Rheum Dis 2002;61(Suppl I):242 [Abstract FRI0300]
   Google Scholar
• Scott G, Branson J, Milosavljev S, Rordorf C, Haraoui B, Ouellet J-P, Schell E. Lumiracoxib demonstrates dose-proportional and time-independent pharmacokinetics in patients with osteoarthritis of the knee. Ann Rheum Dis 2003;62(Suppl I):267 [Abstract FRI0235]
   Google Scholar
• Scott G, Rordorf C, Reynolds C, Kalbag J, Looby M, Milosavljev S, Weaver M, Huff JP, Ruff DA. Pharmacokinetics of lumiracoxib in plasma and synovial fluid. Clin Pharmacokinet 2004;43:467–78
   PubMed Web of Science ®Google Scholar
• Dawson J, Jagher B, Toscano KT, Fujimoto RA, Quadros E. Lumiracoxib shows rapid distribution to inflamed sites in a rat tissue chamber model compared with rofecoxib and celecoxib. Ann Rheum Dis 2003;62(Suppl I):377 [Abstract AB0042]
   Google Scholar
• Weaver ML, Flood DJ, Kimble EF, Fujimoto RA. Lumiracoxib demonstrates preferential distribution to inflamed tissue in the rat following a single oral dose: an effect not seen with other cyclooxygenase-2 inhibitors. Ann Rheum Dis 2003;62(Suppl I):378 [Abstract AB0044]
   Google Scholar
• Day RO. Pharmacokinetic and pharmacodynamic aspects of the ideal COX-2 inhibitor: a rheumatologist's perspective. Clin Exp Rheumatol 2001;19(Suppl 25):S59–62
   PubMedGoogle Scholar
• Hawkey CJ, Svoboda P Fiedorowicz-Fabrycy IF, Nasonov EL, Pikhlak EG, Cousin M, Gitton X, Hoexter G. Gastroduodenal safety and tolerability of lumiracoxib compared with ibuprofen and celecoxib in patients with osteoarthritis. J Rheumatol 2004; 31:1804–10
   Google Scholar
• Kivitz AJ, Nayiager S, Schimansky T, Gimona A, Thurston HJ, Hawkey C. Reduced incidence of gastroduodenal ulcers associated with lumiracoxib compared with ibuprofen in patients with rheumatoid arthritis. Aliment Pharmacol Ther 2004;19:1189–98
   PubMed Web of Science ®Google Scholar
• Hawkey CJ, Farkouh M, Gitton X, Ehrsam E, Huels J, Richardson P. Therapeutic Arthritis Research and Gastrointestinal Event Trial of lumiracoxib – study design and patient demographics. Aliment Pharmacol Ther 2004;20:51–63
   PubMed Web of Science ®Google Scholar
• Schnitzer TJ, Burmester GR, Mysler E, Hochberg MC, Doherty M, Ehrsam E, Gitton X, Krammer G, Mellein B, Matchaba P, Gimona A, Hawkey CJ. TARGET Study Group. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet 2004;364:665–74
   Google Scholar
• Tannenbaum H, Berenbaum F, Reginster J-Y, Zacher J, Robinson J, Poor G, Bliddal H, Uebelhart D, Adami S, Navarro F, Lee A, Moore A, Gimona A. Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a 13-week, randomized, doubleblind study versus placebo and celecoxib. Ann Rheum Dis 2004;63: 1419–26
   Google Scholar
• Fleischmann R, Sheldon E, Maldonado Cocco J, Yu S, Dutta D, Usiskin K. A prospective randomized 13-week study evaluating the efficacy of lumiracoxib in patients with osteoarthritis of the knee. Ann Rheum Dis 2003;62(Suppl I):266 [Abstract FRI0233]
   Google Scholar
• Benevolenskaya L, Tüzün S, Hagin E, Moore A, Gimona A. Lumiracoxib is effective in relieving symptoms of knee or hip osteoarthritis after 4 weeks of treatment: results from a randomized, placebo-controlled trial. Ann Rheum Dis 2003;62(Suppl I):270 [Abstract FRI0246]
   Google Scholar
• Altman R, Asch E, Bloch D, Bole G, Borenstein D, Brandt K, Christy W Cooke TD, Greenwald R, Hochberg M, et al. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Arthritis Rheum 1986;29:1039–49
   Google Scholar
• Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 1988;15:1833–40
   Google Scholar
• Dougados M, Leclaire P, van der Heijde D, Bloch DA, Bellamy N, Altman RD. Response criteria for clinical trials on osteoarthritis of the knee and hip: a report of the Osteoarthritis Research Society International Standing Committee for Clinical Trials response criteria initiative. Osteoarthritis Cartilage 2000; 8:395–403
   PubMed Web of Science ®Google Scholar
• Pham T, Van Der Heijde D, Lassere M, Altman RD, Anderson JJ, Bellamy N, Hochberg M, Simon L, Strand V, Woodworth T, Dougados M. OMERACT-OARSI. Outcome variables for osteoarthritis clinical trials: The OMERACT-OARSI set of responder criteria. J Rheumatol 2003;30:1648–54
   Google Scholar
• Tubach F, Ravaud P, Baron G, Falissard B, Logeart I, Bellamy N, Bombardier C, Felson DT, Hochberg MC, Van Der Heijde D, Dougados M. Evaluation of clinically relevant changes in patient- reported outcomes in knee and hip osteoarthritis: the Minimal Clinically Important Improvement. Ann Rheum Dis 2005; 64:29–33
   Google Scholar
• McKenna F, Borenstein D, Wendt H, Wallemark C, Lefkowith JB, Geis GS. Celecoxib versus diclofenac in the management of osteoarthritis of the knee. Scand J Rheumatol 2001;30:11–18
   PubMed Web of Science ®Google Scholar
• Bensen WG, Fiechtner JJ, McMillen JI, Zhao WW Yu SS, Woods EM, Hubbard RC, Isakson PC, Verburg KM, Geis GS. Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomized controlled trial. Mayo Clin Proc 1999;74: 1095–105
   Google Scholar
• Makarowski W Zhao WW Bevirt T, Recker DP. Efficacy and safety of the COX-2 specific inhibitor valdecoxib in the management of osteoarthritis of the hip: a randomized, double-blind, placebo-controlled comparison with naproxen. Osteoarthritis Cartilage 2002;10:290–6
   PubMed Web of Science ®Google Scholar
• Farkouh ME, Kirshner H, Harrington RA, Ruland S, Verheugt FW Schnitzer TJ, Burmester GR, Mysler E, Hochberg MC, Doherty M, Ehrsam E, Gitton X, Krammer G, Mellein B, Gimona A, Matchaba P, Hawkey CJ, Chesebro JH. TARGET Study Group. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARG ET), cardiovascular outcomes: randomised controlled trial. Lancet 2004;364:675–84
   Google Scholar
• Fitzgerald GA. Coxibs and cardiovascular disease. N Engl J Med 2004;351:1709–11
   PubMed Web of Science ®Google Scholar
• Vioxx: an unequal partnership between safety and efficacy. Lancet 2004;364: 1287–8
   Google Scholar